We request continued funding for the highly successful, Dana-Farber/Harvard Cancer Center (DF/HCC) Program in Cancer Outcomes Research Training (PCORT). PCORT is curriculum-based, highly inter- disciplinary and involves collaboration across the entire DF/HCC. The goal of the Program is to train leaders in cancer outcomes research. We believe that PCORT has sufficient research and training opportunities to provide a comprehensive research training experience, and that our success - and the success of our trainees - justifies this request for continued funding. Funding will allow continued recruitment of 2 new M.D. and/or Ph.D. trainees and 1 new pre-doctoral trainee per year. Because all trainees spend a minimum of 2 years in the Program, we will maintain a total of 6 trainees in the Program at all times. We will recruit individuals with diverse prior research experience and training, and will integrate all trainees into a highly collaborative research environment. We will also actively recruit highly qualified minority and women applicants to the program. The Program has 3 components: 1) a specialized curriculum;2) other didactic experiences;and, 3) mentored, multidisciplinary cancer-related outcomes research. The specialized curriculum includes weekly seminars alternating between didactic lectures and """"""""research-in-progress"""""""" presentations by trainees and faculty. Appropriately qualified trainees also attend the Harvard Program in Clinical Effectiveness, an intensive, seven-week, 15 credit classroom-based program which includes required courses in epidemiology and biostatistics, as well as a variety of electives. Qualified trainees may continue to take courses at HSPH, leading to a Master's degree. Trainees may also attend additional courses throughout Harvard University and its affiliated schools. Trainees will spend the largest part of their time participating in mentored cancer outcomes research under the direct supervision of PCORT faculty. All research projects undertaken by trainees will be multidisciplinary and highly collaborative. Trainees will be exposed to a broad range of cancer outcomes research. Trainees will be evaluated throughout and upon completion of the Program. After successful completion of the training program, they will be well prepared to conduct independent, externally funded, cancer outcomes research, and to do so effectively as part of a multidisciplinary research team.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Education Projects (R25)
Project #
5R25CA092203-09
Application #
7915737
Study Section
Subcommittee G - Education (NCI)
Program Officer
Myrick, Dorkina C
Project Start
2001-07-01
Project End
2012-08-31
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
9
Fiscal Year
2010
Total Cost
$532,555
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Friedrich, Paola; Guerra-García, Pilar; Stetson, Alyssa et al. (2018) Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24:96-102
Melamed, Alexander; Fink, Günther; Wright, Alexi A et al. (2018) Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study. BMJ 360:j5463
Brown, Justin C; Caan, Bette J; Meyerhardt, Jeffrey A et al. (2018) The deterioration of muscle mass and radiodensity is prognostic of poor survival in stage I-III colorectal cancer: a population-based cohort study (C-SCANS). J Cachexia Sarcopenia Muscle 9:664-672
Melamed, Alexander; Margul, Daniel J; Chen, Ling et al. (2018) Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer. N Engl J Med 379:1905-1914
Merker, Vanessa L; Dai, Annie; Radtke, Heather B et al. (2018) Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis. BMC Health Serv Res 18:668
Hinchcliff, Emily; Melamed, Alexander; Bregar, Amy et al. (2018) Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer. Gynecol Oncol 148:168-173
Odejide, Oreofe O; Cronin, Angel M; Earle, Craig C et al. (2017) Why are patients with blood cancers more likely to die without hospice? Cancer 123:3377-3384
Melamed, Alexander; Keating, Nancy L; Clemmer, Joel T et al. (2017) Laparoscopic staging for apparent stage I epithelial ovarian cancer. Am J Obstet Gynecol 216:50.e1-50.e12
Gockley, Allison; Melamed, Alexander; Bregar, Amy J et al. (2017) Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer. Obstet Gynecol 129:439-447
Cauley, Christy E; Anderson, Geoffrey; Haynes, Alex B et al. (2017) Predictors of In-hospital Postoperative Opioid Overdose After Major Elective Operations: A Nationally Representative Cohort Study. Ann Surg 265:702-708

Showing the most recent 10 out of 121 publications